- call +1-201-465-4211
- email sales@mrinsights.biz
Cancer therapy describes the treatment of cancer in a patient, often with surgery, chemotherapy and/or radiotherapy. Targeted therapies are also available for some cancer types. A cancer patient might receive many different types of therapy, including those aimed at relieving the symptoms of cancer, such as pain.
Scope of the Report:
This report studies the Cancer Therapies market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Therapies market by product type and applications/end industries.
North America dominates the global cancer therapy market, owing to high prevalence of cancer in the region because of a sedentary lifestyle, along with launch and growing adoption of novel cancer therapy in the region.
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of cancer, growing awareness regarding cure and treatment of cancer, and increasing collaboration between public and private sectors to provide novel cancer therapy in the region.
The global Cancer Therapies market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Therapies.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Amgen
AstraZeneca
Bristol-Myers Squibb
Bayer AG
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immunological and Vaccine Approaches
Antiproliferative Approaches
Photodynamic Therapy
Gene Therapy Approaches
Cell Cycle and Apoptosis Approaches
Market Segment by Applications, can be divided into
Hospital Use
Clinic Use
Household
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Cancer Therapies Market Overview
1.1 Product Overview and Scope of Cancer Therapies
1.2 Classification of Cancer Therapies by Types
1.2.1 Global Cancer Therapies Revenue Comparison by Types (2017-2023)
1.2.2 Global Cancer Therapies Revenue Market Share by Types in 2017
1.2.3 Immunological and Vaccine Approaches
1.2.4 Antiproliferative Approaches
1.2.5 Photodynamic Therapy
1.2.6 Gene Therapy Approaches
1.2.7 Cell Cycle and Apoptosis Approaches
1.3 Global Cancer Therapies Market by Application
1.3.1 Global Cancer Therapies Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Global Cancer Therapies Market by Regions
1.4.1 Global Cancer Therapies Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Cancer Therapies Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Cancer Therapies Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cancer Therapies Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Cancer Therapies Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cancer Therapies Status and Prospect (2013-2023)
1.5 Global Market Size of Cancer Therapies (2013-2023)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Cancer Therapies Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca
2.2.1 Business Overview
2.2.2 Cancer Therapies Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb
2.3.1 Business Overview
2.3.2 Cancer Therapies Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol-Myers Squibb Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bayer AG
2.4.1 Business Overview
2.4.2 Cancer Therapies Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bayer AG Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.5 F. Hoffmann-La Roche Ltd
2.5.1 Business Overview
2.5.2 Cancer Therapies Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 F. Hoffmann-La Roche Ltd Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.6 GlaxoSmithKline PLC
2.6.1 Business Overview
2.6.2 Cancer Therapies Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GlaxoSmithKline PLC Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.7 Johnson & Johnson
2.7.1 Business Overview
2.7.2 Cancer Therapies Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Johnson & Johnson Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.8 Merck & Co. Inc.
2.8.1 Business Overview
2.8.2 Cancer Therapies Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Merck & Co. Inc. Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.9 Novartis AG
2.9.1 Business Overview
2.9.2 Cancer Therapies Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Novartis AG Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
2.10 Pfizer Inc.
2.10.1 Business Overview
2.10.2 Cancer Therapies Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Pfizer Inc. Cancer Therapies Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cancer Therapies Market Competition, by Players
3.1 Global Cancer Therapies Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Cancer Therapies Players Market Share
3.2.2 Top 10 Cancer Therapies Players Market Share
3.3 Market Competition Trend
4 Global Cancer Therapies Market Size by Regions
4.1 Global Cancer Therapies Revenue and Market Share by Regions
4.2 North America Cancer Therapies Revenue and Growth Rate (2013-2018)
4.3 Europe Cancer Therapies Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Cancer Therapies Revenue and Growth Rate (2013-2018)
4.5 South America Cancer Therapies Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Cancer Therapies Revenue and Growth Rate (2013-2018)
5 North America Cancer Therapies Revenue by Countries
5.1 North America Cancer Therapies Revenue by Countries (2013-2018)
5.2 USA Cancer Therapies Revenue and Growth Rate (2013-2018)
5.3 Canada Cancer Therapies Revenue and Growth Rate (2013-2018)
5.4 Mexico Cancer Therapies Revenue and Growth Rate (2013-2018)
6 Europe Cancer Therapies Revenue by Countries
6.1 Europe Cancer Therapies Revenue by Countries (2013-2018)
6.2 Germany Cancer Therapies Revenue and Growth Rate (2013-2018)
6.3 UK Cancer Therapies Revenue and Growth Rate (2013-2018)
6.4 France Cancer Therapies Revenue and Growth Rate (2013-2018)
6.5 Russia Cancer Therapies Revenue and Growth Rate (2013-2018)
6.6 Italy Cancer Therapies Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Cancer Therapies Revenue by Countries
7.1 Asia-Pacific Cancer Therapies Revenue by Countries (2013-2018)
7.2 China Cancer Therapies Revenue and Growth Rate (2013-2018)
7.3 Japan Cancer Therapies Revenue and Growth Rate (2013-2018)
7.4 Korea Cancer Therapies Revenue and Growth Rate (2013-2018)
7.5 India Cancer Therapies Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Cancer Therapies Revenue and Growth Rate (2013-2018)
8 South America Cancer Therapies Revenue by Countries
8.1 South America Cancer Therapies Revenue by Countries (2013-2018)
8.2 Brazil Cancer Therapies Revenue and Growth Rate (2013-2018)
8.3 Argentina Cancer Therapies Revenue and Growth Rate (2013-2018)
8.4 Colombia Cancer Therapies Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Cancer Therapies by Countries
9.1 Middle East and Africa Cancer Therapies Revenue by Countries (2013-2018)
9.2 Saudi Arabia Cancer Therapies Revenue and Growth Rate (2013-2018)
9.3 UAE Cancer Therapies Revenue and Growth Rate (2013-2018)
9.4 Egypt Cancer Therapies Revenue and Growth Rate (2013-2018)
9.5 Nigeria Cancer Therapies Revenue and Growth Rate (2013-2018)
9.6 South Africa Cancer Therapies Revenue and Growth Rate (2013-2018)
10 Global Cancer Therapies Market Segment by Type
10.1 Global Cancer Therapies Revenue and Market Share by Type (2013-2018)
10.2 Global Cancer Therapies Market Forecast by Type (2018-2023)
10.3 Immunological and Vaccine Approaches Revenue Growth Rate (2013-2023)
10.4 Antiproliferative Approaches Revenue Growth Rate (2013-2023)
10.5 Photodynamic Therapy Revenue Growth Rate (2013-2023)
10.6 Gene Therapy Approaches Revenue Growth Rate (2013-2023)
10.7 Cell Cycle and Apoptosis Approaches Revenue Growth Rate (2013-2023)
11 Global Cancer Therapies Market Segment by Application
11.1 Global Cancer Therapies Revenue Market Share by Application (2013-2018)
11.2 Cancer Therapies Market Forecast by Application (2018-2023)
11.3 Hospital Use Revenue Growth (2013-2018)
11.4 Clinic Use Revenue Growth (2013-2018)
11.5 Household Revenue Growth (2013-2018)
11.6 Other Revenue Growth (2013-2018)
12 Global Cancer Therapies Market Size Forecast (2018-2023)
12.1 Global Cancer Therapies Market Size Forecast (2018-2023)
12.2 Global Cancer Therapies Market Forecast by Regions (2018-2023)
12.3 North America Cancer Therapies Revenue Market Forecast (2018-2023)
12.4 Europe Cancer Therapies Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Cancer Therapies Revenue Market Forecast (2018-2023)
12.6 South America Cancer Therapies Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Cancer Therapies Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Cancer Therapies Picture
Table Product Specifications of Cancer Therapies
Table Global Cancer Therapies and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
